<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01477463</url>
  </required_header>
  <id_info>
    <org_study_id>SKIN0010</org_study_id>
    <secondary_id>SU-10272011-8570</secondary_id>
    <secondary_id>IRB-22207</secondary_id>
    <secondary_id>5K23AR056736</secondary_id>
    <nct_id>NCT01477463</nct_id>
  </id_info>
  <brief_title>Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers</brief_title>
  <official_title>Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the signaling pathways and changes in gene&#xD;
      expression in melanocytes of subjects with a history of non-melanoma skin cancer who are&#xD;
      exposed to oral vitamin D. If vitamin D is found to inhibit a signaling pathway involved in&#xD;
      the development of melanoma such as BRAF, a protein involved in cell proliferation, then oral&#xD;
      vitamin D could be explored further as a chemoprevention for melanoma skin cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      Vitamin D is an important hormone that has multiple genetic effects in different tissue types&#xD;
      that are mediated by signaling through the vitamin D receptor.&#xD;
&#xD;
      Recent studies have shown that vitamin D signaling results in decreased innate immunity and&#xD;
      increased adaptive immunity.&#xD;
&#xD;
      Multiple epidemiologic studies have suggested that vitamin D may play a role in decreasing&#xD;
      the risk of developing multiple types of cancer, including skin cancer.&#xD;
&#xD;
      In the context of the relative success of novel immune-related therapies including PD1&#xD;
      inhibitors, which improves immuno-surveillance, and ipilimumab, which suppresses T cell&#xD;
      response, there is increased promise for treatment strategies that activate innate immunity.&#xD;
      This led us to ask the question of whether vitamin D could increase immune surveillance for&#xD;
      melanoma via increased activity of the adaptive immune system.&#xD;
&#xD;
      Prior studies performed by our group and others have suggested that vitamin D may play a role&#xD;
      in decreasing melanoma risk. An epidemiologic study from the Women's Health Initiative showed&#xD;
      that women with a prior history of NMSC who received calcium and vitamin D supplementation&#xD;
      had a lower risk of subsequently developing melanoma. At the same time, women with a lower&#xD;
      serum vitamin D level had a higher risk of developing melanoma. Furthermore, a recent&#xD;
      clinical study showed that vitamin D supplementation increases serum vitamin D levels and&#xD;
      ultimately results in increased vitamin D receptor signaling in benign nevi.&#xD;
&#xD;
      Taken together, this findings led us to ask whether oral vitamin D supplementation could&#xD;
      impact immune signaling in benign nevi and potentially underpin a theoretical&#xD;
      chemo-preventive role for vitamin D in melanoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Genes That Showed Changes in Expression After Vitamin D Treatment</measure>
    <time_frame>2 years</time_frame>
    <description>Normal cells have a complex series of molecular signals that allow communication between cells and to the cell nucleus. These signals work together to control one or more cell functions, such as cell division or cell death. Abnormal signaling activity caused by changes in gene expression can lead to cancer. An understanding of abnormal signaling, both in the tumor and in normal tissues, may lead to new therapies in cancer patients. We wish to identify changes in molecular signaling that occur in the development of melanoma that might be suppressed in benign nevi (moles) in response to vitamin D supplementation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Genes Differentialy Regulated in Melanoma That Showed Changes in Expression After Vitamin D Treatment</measure>
    <time_frame>2 years</time_frame>
    <description>We utilized a prior gene expression study that compared malignant melanoma cells to benign nevi (moles) and identified over 2300 genes that were differentially regulated in melanoma compared to benign nevi. There were approximately 270 genes in our data set that showed changes in expression after vitamin D treatment. We wish to identify overlap between these two groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vitamin D Toxicity</measure>
    <time_frame>2 years</time_frame>
    <description>serum 25(OH)D for</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Hypercalcemia for Vitamin D Toxicity</measure>
    <time_frame>2 years</time_frame>
    <description>Calcium levels</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Melanoma, Skin</condition>
  <arm_group>
    <arm_group_label>Arm A: Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4,000 IU oral vitamin D3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Placebo + Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo + 4000 IU oral Vitamin D3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>4,000 IU oral vitamin D3</description>
    <arm_group_label>Arm A: Vitamin D</arm_group_label>
    <other_name>25-hydroxy D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo and vitamin D</intervention_name>
    <arm_group_label>Arm B: Placebo + Vitamin D</arm_group_label>
    <other_name>inactive tablet and 25-hydroxy D3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 - 75&#xD;
&#xD;
          2. Female&#xD;
&#xD;
          3. White race/ethnicity&#xD;
&#xD;
          4. With history of non-melanoma skin cancer&#xD;
&#xD;
          5. Has 12-16 moles upon skin examination&#xD;
&#xD;
          6. Consents to 6-12 moles biopsies over 2-3 clinic visits (2-4 months)&#xD;
&#xD;
          7. Consents to ingesting oral vitamin D3 or placebo daily for 2-4 months&#xD;
&#xD;
          8. Consents to abstaining from other multivitamins during study&#xD;
&#xD;
          9. Consents to research use of their tissue and blood samples&#xD;
&#xD;
         10. Agrees to apply a sunscreen of SPF 45 during study -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or current evidence of hyperparathyroidism, hypercalcemia, renal calculi, or&#xD;
             other renal disease.&#xD;
&#xD;
          2. History or current evidence of malabsorptive illnesses, such as IBD, or liver disease&#xD;
             that would impair uptake or metabolism of vitamin D.&#xD;
&#xD;
          3. History or current evidence of hyperthyroidism that would increase metabolism of&#xD;
             vitamin D.&#xD;
&#xD;
          4. History or current evidence of immunosuppression (cancer, autoimmune disease) or&#xD;
             taking immunosuppressive drugs.&#xD;
&#xD;
          5. Currently taking medications that would affect metabolism of vitamin D&#xD;
             (anticonvulsants, corticosteroids, H2-receptor antagonists).&#xD;
&#xD;
          6. Currently taking medications that predispose to hypercalcemia (digoxin, lithium,&#xD;
             thiazide diuretics) or other electrolyte disturbances (aluminum hydroxide)&#xD;
&#xD;
          7. Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Y Tang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Cancer Institute</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>November 17, 2011</study_first_submitted>
  <study_first_submitted_qc>November 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2011</study_first_posted>
  <results_first_submitted>June 30, 2016</results_first_submitted>
  <results_first_submitted_qc>October 31, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 23, 2016</results_first_posted>
  <last_update_submitted>October 31, 2016</last_update_submitted>
  <last_update_submitted_qc>October 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Jean Yuh Tang</investigator_full_name>
    <investigator_title>Associate Professor of Dermatology</investigator_title>
  </responsible_party>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Results will be submitted to scientific journal for publication.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm A: Vitamin D</title>
          <description>4,000 IU oral vitamin D3&#xD;
Vitamin D3: 4,000 IU oral vitamin D3</description>
        </group>
        <group group_id="P2">
          <title>Arm B: Placebo</title>
          <description>Placebo - patients may cross over to vitamin D3 treatment after placebo treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A: Vitamin D</title>
          <description>4,000 IU oral vitamin D3&#xD;
Vitamin D3: 4,000 IU oral vitamin D3</description>
        </group>
        <group group_id="B2">
          <title>Arm B: Placebo</title>
          <description>Placebo - subjects may cross over to vitamin D treatment after placebo treatment is complete</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.2" spread="12.6"/>
                    <measurement group_id="B2" value="55.8" spread="5.7"/>
                    <measurement group_id="B3" value="56.1" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Genes That Showed Changes in Expression After Vitamin D Treatment</title>
        <description>Normal cells have a complex series of molecular signals that allow communication between cells and to the cell nucleus. These signals work together to control one or more cell functions, such as cell division or cell death. Abnormal signaling activity caused by changes in gene expression can lead to cancer. An understanding of abnormal signaling, both in the tumor and in normal tissues, may lead to new therapies in cancer patients. We wish to identify changes in molecular signaling that occur in the development of melanoma that might be suppressed in benign nevi (moles) in response to vitamin D supplementation.</description>
        <time_frame>2 years</time_frame>
        <population>All subjects treated with vitamin D3.</population>
        <group_list>
          <group group_id="O1">
            <title>All Patients Treated With Vitamin D3</title>
            <description>4,000 IU oral vitamin D3&#xD;
Vitamin D3: 4,000 IU oral vitamin D3</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Genes That Showed Changes in Expression After Vitamin D Treatment</title>
          <description>Normal cells have a complex series of molecular signals that allow communication between cells and to the cell nucleus. These signals work together to control one or more cell functions, such as cell division or cell death. Abnormal signaling activity caused by changes in gene expression can lead to cancer. An understanding of abnormal signaling, both in the tumor and in normal tissues, may lead to new therapies in cancer patients. We wish to identify changes in molecular signaling that occur in the development of melanoma that might be suppressed in benign nevi (moles) in response to vitamin D supplementation.</description>
          <population>All subjects treated with vitamin D3.</population>
          <units>number of genes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Genes Differentialy Regulated in Melanoma That Showed Changes in Expression After Vitamin D Treatment</title>
        <description>We utilized a prior gene expression study that compared malignant melanoma cells to benign nevi (moles) and identified over 2300 genes that were differentially regulated in melanoma compared to benign nevi. There were approximately 270 genes in our data set that showed changes in expression after vitamin D treatment. We wish to identify overlap between these two groups.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients Treated With Vitamin D3</title>
            <description>4,000 IU oral vitamin D3&#xD;
Vitamin D3: 4,000 IU oral vitamin D3</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Genes Differentialy Regulated in Melanoma That Showed Changes in Expression After Vitamin D Treatment</title>
          <description>We utilized a prior gene expression study that compared malignant melanoma cells to benign nevi (moles) and identified over 2300 genes that were differentially regulated in melanoma compared to benign nevi. There were approximately 270 genes in our data set that showed changes in expression after vitamin D treatment. We wish to identify overlap between these two groups.</description>
          <units>number of genes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vitamin D Toxicity</title>
        <description>serum 25(OH)D for</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Vitamin D</title>
            <description>4,000 IU oral vitamin D3&#xD;
Vitamin D3: 4,000 IU oral vitamin D3</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo</title>
            <description>Placebo (inactive capsule)</description>
          </group>
        </group_list>
        <measure>
          <title>Vitamin D Toxicity</title>
          <description>serum 25(OH)D for</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.11" spread="14.5"/>
                    <measurement group_id="O2" value="29.83" spread="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Hypercalcemia for Vitamin D Toxicity</title>
        <description>Calcium levels</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Vitamin D</title>
            <description>4,000 IU oral vitamin D3&#xD;
Vitamin D3: 4,000 IU oral vitamin D3</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo</title>
            <description>Placebo - inactive capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Hypercalcemia for Vitamin D Toxicity</title>
          <description>Calcium levels</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm A: Vitamin D</title>
          <description>4,000 IU oral vitamin D3&#xD;
Vitamin D3: 4,000 IU oral vitamin D3</description>
        </group>
        <group group_id="E2">
          <title>Arm B: Placebo</title>
          <description>Placebo (inactive capsule)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jean Y Tang MD PhD, assistant professor</name_or_title>
      <organization>Stanford University School of Medicine</organization>
      <phone>650-721-7149</phone>
      <email>baileyhi@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

